Parkinson’s disease is the most common movement disorder and the second most common neurodegenerative disease. In addition to motor symptoms such as joint stiffness and gait abnormalities, many Parkinson’s patients experience cognitive impairment during the course of their lives including attention difficulties, forgetfulness, and slow thought processes. These symptoms cause a tremendous amount of distress and disability in PD patients. 

During the past fifteen years, abnormalities in mitochondrial structure and function have been identified as highly prominent in Parkinson’s disease. These mitochondrial abnormalities have been shown to occur early in the course of Parkinson’s disease, often predating the occurrence of clinical symptoms.

We will put in place a well-defined mitochondrial support program designed to decrease oxidative stress and promote mitochondrial repair with the goal of improving brain function and stabilizing PD symptoms. Quantitative testing (UPDRS) can be followed regularly to monitor the effects of the treatment program on both motor and cognitive symptoms.